These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 17339481)

  • 1. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.
    Herber D; Brown TP; Liang S; Young DA; Collins M; Dunussi-Joannopoulos K
    J Immunol; 2007 Mar; 178(6):3822-30. PubMed ID: 17339481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice.
    Rankin AL; Guay H; Herber D; Bertino SA; Duzanski TA; Carrier Y; Keegan S; Senices M; Stedman N; Ryan M; Bloom L; Medley Q; Collins M; Nickerson-Nutter C; Craft J; Young D; Dunussi-Joannopoulos K
    J Immunol; 2012 Feb; 188(4):1656-67. PubMed ID: 22231702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
    J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
    Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C
    J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-21 receptor blockade inhibits secondary humoral responses and halts the progression of preestablished disease in the (NZB × NZW)F1 systemic lupus erythematosus model.
    Zhang M; Yu G; Chan B; Pearson JT; Rathanaswami P; Delaney J; Ching Lim A; Babcook J; Hsu H; Gavin MA
    Arthritis Rheumatol; 2015 Oct; 67(10):2723-31. PubMed ID: 26097207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the Parent→F1 Graft-versus-Host Disease Model.
    Nguyen V; Rus H; Chen C; Rus V
    J Immunol; 2016 Feb; 196(4):1529-40. PubMed ID: 26792801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
    Yang J; Li Q; Yang X; Li M
    Mol Med; 2015 Apr; 21(1):364-70. PubMed ID: 25902303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-
    Wada Y; Gonzalez-Sanchez HM; Weinmann-Menke J; Iwata Y; Ajay AK; Meineck M; Kelley VR
    J Am Soc Nephrol; 2019 Feb; 30(2):244-259. PubMed ID: 30622154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-33 neutralization suppresses lupus disease in lupus-prone mice.
    Li P; Lin W; Zheng X
    Inflammation; 2014 Jun; 37(3):824-32. PubMed ID: 24398614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-10 regulates murine lupus.
    Yin Z; Bahtiyar G; Zhang N; Liu L; Zhu P; Robert ME; McNiff J; Madaio MP; Craft J
    J Immunol; 2002 Aug; 169(4):2148-55. PubMed ID: 12165544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siglec-G deficiency leads to more severe collagen-induced arthritis and earlier onset of lupus-like symptoms in MRL/lpr mice.
    Bökers S; Urbat A; Daniel C; Amann K; Smith KG; Espéli M; Nitschke L
    J Immunol; 2014 Apr; 192(7):2994-3002. PubMed ID: 24600033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
    Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell apoptosis accelerates the onset of murine lupus.
    Trébéden-Nègre H; Weill B; Fournier C; Batteux F
    Eur J Immunol; 2003 Jun; 33(6):1603-12. PubMed ID: 12778478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice.
    Lenda DM; Stanley ER; Kelley VR
    J Immunol; 2004 Oct; 173(7):4744-54. PubMed ID: 15383612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
    Mihaylova N; Bradyanova S; Chipinski P; Chausheva S; Kyurkchiev D; Tchorbanov AI
    Scand J Immunol; 2020 Sep; 92(3):e12915. PubMed ID: 32533866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
    Cai Z; Wong CK; Dong J; Chu M; Jiao D; Kam NW; Lam CW; Tam LS
    Clin Exp Immunol; 2015 Aug; 181(2):253-66. PubMed ID: 25845911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice.
    Monneaux F; Dumortier H; Steiner G; Briand JP; Muller S
    Int Immunol; 2001 Sep; 13(9):1155-63. PubMed ID: 11526096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell-derived IFN-γ downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus.
    Düster M; Becker M; Gnirck AC; Wunderlich M; Panzer U; Turner JE
    Eur J Immunol; 2018 Aug; 48(8):1364-1375. PubMed ID: 29671873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
    Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
    Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
    Kikawada E; Lenda DM; Kelley VR
    J Immunol; 2003 Apr; 170(7):3915-25. PubMed ID: 12646661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.